UBS Group
NBRV

UBS Group’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

UBS Group’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,315
Closed -$2.3K – 10424
2023
Q1 		$2.3K Buy
1,315
+323
+33% +$543 ﹤0.01% 8535
2022
Q4 		$1.88K Buy
992
+611
+160% +$1.35K ﹤0.01% 9775
2022
Q3 		$1K Sell
381
-886
-70% -$3.73K ﹤0.01% 10251
2022
Q2 		$6K Buy
1,267
+36
+3% +$235 ﹤0.01% 8819
2022
Q1 		$13K Buy
+1,231
New +$15K ﹤0.01% 8139
2020
Q2 		– Sell
-22
Closed -$3K – 8618
2020
Q1 		$3K Buy
+22
New +$6.73K ﹤0.01% 7569
2019
Q4 		– Sell
-28
Closed -$14K – 8616
2019
Q3 		$14K Sell
28
-18
-39% -$10.2K ﹤0.01% 6977
2019
Q2 		$28K Buy
46
+5
+12% +$3.07K ﹤0.01% 6398
2019
Q1 		$25K Sell
41
-109
-73% -$59.5K ﹤0.01% 6126
2018
Q4 		$55K Buy
150
+100
+200% +$53.8K ﹤0.01% 6013
2018
Q3 		$34K Sell
50
-30
-38% -$21.3K ﹤0.01% 6454
2018
Q2 		$69K Buy
80
+9
+13% +$10.3K ﹤0.01% 5742
2018
Q1 		$90K Buy
71
+52
+274% +$76.9K ﹤0.01% 5287
2017
Q4 		$29K Buy
19
+14
+280% +$22.1K ﹤0.01% 6275
2017
Q3 		$10K Buy
+5
New +$11.7K ﹤0.01% 6913
2017
Q1 		– Sell
-5
Closed -$7K – 8148
2016
Q4 		$7K Buy
+5
New +$6.64K ﹤0.01% 7116
2016
Q2 		– Sell
-5
Closed -$12K – 8091
2016
Q1 		$12K Hold
5
– – ﹤0.01% 6558
2015
Q4 		$13K Buy
+5
New +$12.2K ﹤0.01% 7137

Other funds holding NBRV

VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
AA
Addison Advisors Middlebury, Vermont $212M AUM 18.02% 1-Year Est. Return

UBS Group's NBRV Position: Q2 2023 in Review

UBS Group sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2023, closing a stake of 1,315 shares — an estimated $2.3K sold.

UBS Group first reported a position in NBRV in Q4 2015 and held it in 18 quarters. The position peaked at $90K in Q1 2018. 9 funds tracked by Wall St. Rank hold NBRV as of Q2 2023.

  • UBS Group reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 1,315 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2023, an estimated $2.3K.
  • UBS Group first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2015 and held it in 18 quarters.
  • UBS Group's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $90K in Q1 2018.
  • 9 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.